Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2008
12/30/2008US7470441 Method for preparing Mucuna pruriens seed extract
12/30/2008CA2446903C Imidazo ¬1,5-a| pyrimido ¬5,4-d| benzazepine derivatives as gaba a receptor modulators
12/30/2008CA2441771C Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i
12/30/2008CA2412560C Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
12/30/2008CA2391293C .beta.2-adrenergic receptor agonists
12/30/2008CA2381354C Utilisation de la cyamemazine dans le traitement du sevrage brutal aux benzodiazepines
12/30/2008CA2365079C Antiperspirant structured emulsion compositions
12/30/2008CA2364258C 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
12/30/2008CA2356300C 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
12/30/2008CA2312098C A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
12/30/2008CA2245587C Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
12/30/2008CA2189351C Narcotic containing aerosol formulation
12/30/2008CA2162924C New peptide antagonists at glutamate and nmda receptors
12/25/2008US20080319167 Clostridial toxin derivatives able to modify peripheral sensory afferent functions
12/25/2008US20080319165 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least one neuropeptide
12/25/2008US20080319083 Medicine for transnasal administration
12/25/2008US20080319068 Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same
12/25/2008US20080319065 Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release
12/25/2008US20080319051 Liquiritigenin and derivatives as selective estrogen receptor beta agonists
12/25/2008US20080319046 Substituted sulfonamide-indoles
12/25/2008US20080319044 Compounds and Methods of Use Thereof
12/25/2008US20080319032 Tetrahydrobenzothiazole analogues as neuroprotective agents
12/25/2008US20080319030 Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
12/25/2008US20080319027 Composition and Method for Treating Fibrotic Diseases
12/25/2008US20080319025 Therapeutic and Diagnostic Methods Dependent on CYP2A Enzymes
12/25/2008US20080319022 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
12/25/2008US20080319020 4-Oxadiazolyl-Piperidine Compounds and Use Thereof
12/25/2008US20080319019 Therapeutic Agents
12/25/2008US20080319013 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds
12/25/2008US20080319012 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
12/25/2008US20080319000 Use of 3,1IB-Cis-Dihydrotetrabenazine for the Treatment of Symptoms of Huntingtons Disease
12/25/2008US20080318999 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
12/25/2008US20080318997 Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
12/25/2008US20080318996 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
12/25/2008US20080318992 Method of using a pkc inhibitor to reverse prefrontal cortical declines
12/25/2008US20080318991 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
12/25/2008US20080318990 Spiroindolines as modulators of chemokine receptors
12/25/2008US20080318981 Novel Compounds 480
12/25/2008US20080318980 USE OF 7-(PYRIMIDIN-4 YL)-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONES AS GSK-3BETA INHIBITORS
12/25/2008US20080318976 Alpha-Hydroxy Amides as Bradykinin Antagonists or Inverse Agonists
12/25/2008US20080318973 Urotensin II receptor antagonists
12/25/2008US20080318972 5-ht1a receptor subtype agonist
12/25/2008US20080318964 Deuterium-enriched eszopiclone
12/25/2008US20080318960 PAR2-modulating compounds and their use
12/25/2008US20080318953 such as (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid benzyl ester, used as potassium channel modulators for the treatment of nervous system disorders; epilepsy; anxiety disorders; neuropathic pain; headaches; neurodegenerative disorders
12/25/2008US20080318952 Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
12/25/2008US20080318945 Novel Compounds
12/25/2008US20080318944 N-aroyl cyclic amine derivatives as orexin receptor antagonists
12/25/2008US20080318943 Compounds and Uses Thereof - 848
12/25/2008US20080318941 4' substituted compounds having 5-ht6 receptor affinity
12/25/2008US20080318940 Quinazolinone Derivatives as Vanilloid Antagonists
12/25/2008US20080318937 Tricyclic delta-opioid modulators
12/25/2008US20080318933 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders
12/25/2008US20080318932 Sodium Channel Blocker Compositions and the Use Thereof
12/25/2008US20080318927 Substituted monocyclic CGRP receptor antagonists
12/25/2008US20080318926 Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
12/25/2008US20080318925 Compounds and Uses Thereof - 849
12/25/2008US20080318923 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
12/25/2008US20080318917 Polyethylene glycolated superoxide dismutase mimetics
12/25/2008US20080318914 Treating a traumatic brain injury by administering progesterone; dosing regime is constant or two-level, e.g., administering a higher hourly dose followed by a second time period during which a lower hourly dose is administered
12/25/2008US20080318911 20-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof
12/25/2008US20080318899 Pyridazine Compounds, Compositions and Methods
12/25/2008US20080318882 Method of Delivery of Nucleic Acids to Peripheral Neurons
12/25/2008US20080318871 Treatment of neurological disorders
12/25/2008US20080318864 Methods and compositions regarding polychalcogenide compositions
12/25/2008US20080318860 High Activity Growth Factor Mutants
12/25/2008US20080318854 Method for regulating neurite growth
12/25/2008US20080318338 Drug screening using a high affinity form of Heat Shock Protein-90 (HSP90) that has a 17-allylamino-geldanamycin (17-AAG) binding affinity
12/25/2008US20080318293 Sulfotransferase Inhibitors
12/25/2008US20080317885 Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
12/25/2008US20080317883 Methods for treating depression
12/25/2008US20080317873 Pain Relief Compositions
12/25/2008US20080317869 Method and compositions for treatment of ADD/ADHD, depression, memory problems and other conditions
12/25/2008US20080317868 Composition for improving membrane composition and functioning cells
12/25/2008US20080317854 Process for the production of an abuse-proofed solid dosage form
12/25/2008US20080317849 Method for Improving the Medical Treatment of Pain
12/25/2008US20080317847 Hydrostatic delivery system for controlled delivery of agent
12/25/2008US20080317843 Nanoparticulate formulations of modafinil
12/25/2008US20080317834 Compounds and methods for modulating cerebral amyloid angiopathy
12/25/2008US20080317832 Transdermal delivery system comprising glycopyrrolate to treat sialorrhea
12/25/2008US20080317805 Locally administrated low doses of corticosteroids
12/25/2008US20080317783 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and a substance P targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction
12/25/2008US20080317782 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and a substance P targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction
12/25/2008US20080317767 Tripartitle Raftophilic Strutures and their Use
12/25/2008US20080317732 Amyloid Peptide Inactivating Enzyme to Treat Alzheimer's Disease Peripherally
12/25/2008US20080317711 Treatment of Optic Neuritis
12/24/2008WO2008157627A1 Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
12/24/2008WO2008157562A2 Deuterium-enriched olanzapine
12/24/2008WO2008157500A1 Aminoquinazoline cannabinoid receptor modulators for treatment of disease
12/24/2008WO2008157460A1 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
12/24/2008WO2008157408A2 Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
12/24/2008WO2008157404A2 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
12/24/2008WO2008157302A2 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
12/24/2008WO2008157271A1 Deuterium-enriched escitalopram
12/24/2008WO2008157216A1 Process for the manufacture of benzylsulfonylarenes
12/24/2008WO2008157191A2 Quinazoline derivatives as pi3 kinase inhibitors
12/24/2008WO2008156749A1 Combination therapy for depression
12/24/2008WO2008156622A1 Humanized antibodies to amyloid beta
12/24/2008WO2008156621A1 Monoclonal anti beta amyloid antibody
12/24/2008WO2008156418A1 A method for screening or diagnosis of postpolio syndrome and fibromyalgia
1 ... 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 ... 1833